Tumor Biology

, Volume 34, Issue 6, pp 3865–3869

Significant association between XRCC3 C241T polymorphism and increased risk of hepatocellular carcinoma: a meta-analysis

  • Dan Wu
  • Honglei Jiang
  • Hao Yu
  • Dong Xu
  • Jian Liang
  • Junzhe Jin
Research Article

Abstract

Many studies were published to examine the association between XRCC3 C241T polymorphism and hepatocellular carcinoma risk, but their results were inconsistent. To assess the association between XRCC3 C241T polymorphism and hepatocellular carcinoma risk more precisely, a meta-analysis was performed. PubMed, Embase and Wanfang databases were searched for relevant case–control studies. Data were extracted, and the pooled odds ratios (OR) with 95 % confidence intervals (95 % CI) were calculated. Finally, seven studies comprising 2,288 cases with hepatocellular carcinoma and 3,249 controls were included into the meta-analysis. Overall, there was an obvious association between XRCC3 C241T polymorphism and increased risk of hepatocellular carcinoma (TT versus CC: OR = 3.31, 95 % CI 1.52–7.19, P = 0.003; TT versus CC/CT: OR = 3.31, 95 % CI 1.81–6.06, P < 0.001). After adjusting for heterogeneity, there was still an obvious association between XRCC3 C241T polymorphism and increased risk of hepatocellular carcinoma (TT versus CC: OR = 1.92, 95 % CI 1.13–3.26, P = 0.016; TT versus CC/CT: OR = 2.10, 95 % CI 1.25–3.55, P = 0.005). Overall, there is a significant association between XRCC3 C241T polymorphism and increased risk of hepatocellular carcinoma. Further studies are needed to further assess the association in Caucasians.

Keywords

XRCC3 Polymorphism Hepatocellular carcinoma Meta-analysis 

References

  1. 1.
    El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–73. e1261.PubMedCrossRefGoogle Scholar
  2. 2.
    Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123–35.PubMedCrossRefGoogle Scholar
  3. 3.
    Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57:399–408.PubMedCrossRefGoogle Scholar
  4. 4.
    Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis c virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–37.PubMedCrossRefGoogle Scholar
  5. 5.
    Nishida N, Kudo M. Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. Oncology. 2013;84 Suppl 1:93–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Castel SE, Martienssen RA. RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond. Nat Rev Genet. 2013;14:100–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Marshall AL, Christiani DC. Genetic susceptibility to lung cancer—light at the end of the tunnel? Carcinogenesis. 2013;34:487–502.PubMedCrossRefGoogle Scholar
  8. 8.
    Gopalakrishnan V, Raghavan SC. Sequence and structural basis for chromosomal fragility during translocations in cancer. Future Oncol. 2012;8:1121–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Karahalil B, Bohr VA, Wilson 3rd DM. Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk. Hum Exp Toxicol. 2012;31:981–1005.PubMedCrossRefGoogle Scholar
  10. 10.
    Manuguerra M, Saletta F, Karagas MR, Berwick M, Veglia F, Vineis P, et al. Xrcc3 and xpd/ercc2 single nucleotide polymorphisms and the risk of cancer: a huge review. Am J Epidemiol. 2006;164:297–302.PubMedCrossRefGoogle Scholar
  11. 11.
    Qiu LX, Mao C, Yao L, Yu KD, Zhan P, Chen B, et al. Xrcc3 5′-utr and ivs5-14 polymorphisms and breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2010;122:489–93.PubMedCrossRefGoogle Scholar
  12. 12.
    Long XD, Ma Y, Deng ZL, Huang YZ, Wei NB. Association of the thr241met polymorphism of DNA repair gene xrcc3 with genetic susceptibility to afb1-related hepatocellular carcinoma in Guangxi population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008;25:268–71.PubMedGoogle Scholar
  13. 13.
    Long XD, Ma Y, Qu de Y, Liu YG, Huang ZQ, Huang YZ, et al. The polymorphism of xrcc3 codon 241 and afb1-related hepatocellular carcinoma in Guangxi population, china. Ann Epidemiol. 2008;18:572–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Han X, Xing Q, Li Y, Sun J, Ji H, Huazheng P, et al. Study on the DNA repair gene xrcc1 and xrcc3 polymorphism in prediction and prognosis of hepatocellular carcinoma risk. Hepatogastroenterology. 2012;59:2285–9.PubMedGoogle Scholar
  15. 15.
    Zeng X, Liu S, Yu H, Ji L, Li L, Huang J, et al. DNA repair capacity, DNA-strand break repair gene polymorphisms and the incidence of hepatocellular carcinoma in southwestern Guangxi of china. DNA Cell Biol. 2012;31:1384–91.PubMedCrossRefGoogle Scholar
  16. 16.
    Gulnaz A, Sayyed AH, Amin F, Khan A, Aslam MA, Shaikh RS, et al. Association of xrcc1, xrcc3 and xpd genetic polymorphism with an increased risk of hepatocellular carcinoma because of the hepatitis B and C virus. Eur J Gastroenterol Hepatol. 2013;25:166–79.PubMedCrossRefGoogle Scholar
  17. 17.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  18. 18.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  19. 19.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  20. 20.
    Zeng XY, Yu HP, Qiu X, Ji L. Correlation of polymorphism of DNA repair gene xrcc3 with susceptibility to hepatocellular carcinoma in regions of high HCC incidence rate in Guangxi. Chin J Cancer Prev Treat. 2009;14:1056–9.Google Scholar
  21. 21.
    Liu W, Hu ZJ. The relation between genetic polymorphism of DNA repair gene xrcc3、xrcc4 and susceptibility to primary hepatocellular carcinoma. Wanfang Doctoral Dissertation 2010; Fujian Medical University; 2010.Google Scholar
  22. 22.
    Jin F, Xiong WJ, Jing JC, Feng Z, Qu LS, Shen XZ. Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review. J Cancer Res Clin Oncol. 2011;137:1095–104.PubMedCrossRefGoogle Scholar
  23. 23.
    Thursz M, Yee L, Khakoo S. Understanding the host genetics of chronic hepatitis B and C. Semin Liver Dis. 2011;31:115–27.PubMedCrossRefGoogle Scholar
  24. 24.
    Nahon P, Zucman-Rossi J. Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol. 2012;57:663–74.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang RC, Mou SH. Polymorphisms of excision repair gene xpd lys751gln and hogg1 ser326cys might not be associated with hepatocellular carcinoma risk: a meta-analysis. Tumour Biol. 2013;34:901–7.PubMedCrossRefGoogle Scholar
  26. 26.
    He XF, Wei W, Li JL, Shen XL, Ding DP, Wang SL, et al. Association between the xrcc3 t241m polymorphism and risk of cancer: evidence from 157 case–control studies. Gene. 2013;523:10–9.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Dan Wu
    • 1
  • Honglei Jiang
    • 2
  • Hao Yu
    • 2
  • Dong Xu
    • 2
  • Jian Liang
    • 2
  • Junzhe Jin
    • 2
  1. 1.Department of Infectious DiseaseShengjing Hospital of China Medical UniversityShenyangChina
  2. 2.Department of Hepatobiliary SurgeryThe Fourth Affiliated Hospital of China Medical UniversityShenyangChina

Personalised recommendations